Adolescents and Young Adults with HIV
DHHS Last Updated: June 2021Australian Commentary Last Updated: July 2023 AU Comment: Adolescents and young adults with HIV in Australia In 2021, 4/745 (0.5%) of all new HIV notifications in Australia were among individuals aged 19 years or younger, with the majority (3/4) of these notifications among those aged 15-19 years. Reference: King J, McManus […]
HIV-2 Infection
DHHS Last Updated: December 2023Australian Commentary Last Updated: February 2024 AU Comment: HIV-2 Infection in Australia HIV-2 is uncommon in Australia. Diagnosis of HIV-2 in Australia can be difficult because of the cross-reaction of serological tests with HIV-1 proteins. St Vincent’s Hospital, Sydney, and the Victorian Infectious Diseases Reference Laboratory (VIDRL) offers an HIV-2 western […]
HIV and the Older Person
DHHS Last Updated: September 2024Australian Commentary Last Updated: January 2025 AU Comment: Australian Cardiovascular risk calculator An HIV-specific cardiovascular risk calculator has been developed based on data from the D:A:D study (including the use of specific antiretroviral agents), but has not been validated in other populations. The Australian Absolute Cardiovascular Disease Risk Calculator is recommended for […]
Substance Use Disorders and HIV
DHHS Last Updated: September 2024Australian Commentary Last Updated: December 2024 Key Considerations and Recommendations Substance use disorders (SUDs) are prevalent among people with HIV and contribute to poor health outcomes; therefore, screening for SUDs should be a routine part of clinical care (AII). The most commonly used substances among people with HIV include the following (listed in […]
Transplantation in People With HIV
DHHS Last Updated: September 2024Australian Commentary Last Updated: February 2025 Panel’s Recommendations People with HIV who are eligible for solid organ transplant (SOT) or hematopoietic cell transplant (HCT) should have equitable access to transplant (AII). People with HIV should be managed by a multidisciplinary team before, during, and after transplant (AIII). Transplant candidates with HIV should be […]
Transgender People with HIV
DHHS Last Updated: September 2024Australian Commentary Last Updated: December 2024 AU Comment: Transgender People with HIV in Australia. The barriers transgender people face engaging in care are universal and result from stigma, structural barriers and previous negative experiences of health care. These barriers may impact positive health outcomes such as viral suppression. Although accurate data […]
Women with HIV
DHHS Last Updated: September 2024Australian Commentary Last Updated: December 2024 AU Comment: HPV Screening in women living with HIV In Australia, the National Cervical Screening Program (NCSP) guidelines recommend to the general population that cytological screening is replaced with 5 yearly HPV testing, with reflex liquid-based cytology and genotyping for positive samples. HIV-positive women have […]
Special Populations
Special Patient Populations This section has information on Special Patient Populations. Please click on the below links or follow the table of contents to access the information you are looking for. Women with HIV Transgender People with HIV Substance Use Disorders and HIV HIV and the Older Person HIV-2 Infection Adolescents and Young Adults with […]
Hep B/HIV
Hepatitis B Virus/HIV Coinfection DHHS Last Updated: September 2024Australian Commentary Last Updated: January 2025 AU Comment: Australian epidemiology Approximately 5% of Australia’s 26,500 people living with HIV also have chronic hepatitis B. GESA Australian consensus recommendations also suggests HDV testing in the context of HIV/HBV coinfection.Reference: Hepatitis B Consensus Statement Working Group. Australian consensus recommendations for […]
HCV/HIV
Hepatitis C Virus/HIV Coinfection AU Comment: Hepatitis C Treatment in the Australian Context The PBS lists the following all-oral pan genotypic regimens for the treatment of chronic hepatitis C infection in Australia, regardless of liver disease stage or ongoing drug and alcohol use. Treatment naïve: Sofosbuvir + Velpatasvir OR Glecaprevir + Pibrentasvir Treatment experienced: sofosbuvir+velpatasvir+ voxilaprevir (Vosevi) […]